Erasca’s RAS-Targeting Drug Shows Promising Results in Pancreatic and Lung Cancer Trials

Biotechnology company Erasca has reported promising early results from a Phase 1 clinical trial of its experimental cancer drug, ERAS-0015, showing tumor shrinkage in a significant portion of patients with advanced pancreatic and non-small cell lung cancer. The findings, announced on Monday, April 27, 2026, suggest the drug may offer a new approach to targeting RAS mutations, a long-standing challenge in oncology.

Trial Results Exceed Expectations

The preliminary data, collected from studies conducted in the U.S. And China, revealed that ERAS-0015 shrank tumors in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced non-small cell lung cancer (NSCLC). Among a subset of lung cancer patients who had previously failed both immunotherapy and platinum-based chemotherapy, the response rate rose to 75%. These results were described by the company as exceeding its initial expectations.

Jonathan Lim, M.D., chairman, CEO, and co-founder of Erasca, expressed cautious optimism about the findings. I’m excited about both datasets, but I think lung is more definitive at this point. The pancreatic results are maturing, but are very, very promising, Lim told STAT. He added that all options are on the table regarding the drug’s future development.

A New Approach to a Notorious Target

The RAS family of proteins has long been considered a difficult target in cancer treatment. When mutated, these proteins drive uncontrolled cell growth in some of the most aggressive and lethal cancers, including pancreatic, lung, and colorectal cancers. For decades, RAS mutations were labeled “undruggable” due to their complex biology and lack of clear binding sites for traditional drugs.

ERAS-0015 represents a novel approach as a pan-RAS “molecular glue.” Unlike conventional inhibitors that block a single mutated protein, ERAS-0015 is designed to force the cell’s own waste-disposal machinery to tag and destroy multiple forms of faulty RAS proteins. This mechanism could potentially address a broader range of RAS-driven cancers than existing therapies.

Comparisons to Competing Therapies

The results for ERAS-0015 compare favorably to those of daraxonrasib, a similar RAS-targeting drug developed by Revolution Medicines. In a recent trial, daraxonrasib demonstrated a doubling of overall survival in patients with advanced pancreatic cancer. While direct comparisons between early-stage trials are not definitive, Erasca’s data has generated enthusiasm among investors and researchers.

Erasca’s market capitalization has surged to $6.68 billion, reflecting investor confidence in the drug’s potential. The company has stated it has sufficient cash to fund operations into the second half of 2028, providing a substantial runway to advance ERAS-0015 through further clinical development.

Limitations and Next Steps

While the early results are encouraging, experts caution that Phase 1 trials are primarily designed to assess safety and dosing, not efficacy. The data presented by Erasca are still preliminary, and larger, randomized trials will be needed to confirm the drug’s benefits and compare it directly to existing treatments.

The company has not yet released detailed safety data, though it has described the drug as well-tolerated in the trial. Common side effects associated with RAS-targeted therapies can include gastrointestinal issues, fatigue, and liver enzyme elevations, but the full safety profile of ERAS-0015 will become clearer as the trial progresses.

Erasca has indicated that it plans to expand the trial to include additional patient populations and explore combination therapies. The company is also evaluating the drug’s potential in other RAS-driven cancers, such as colorectal cancer, which shares similar genetic mutations.

Broader Implications for Cancer Treatment

The development of ERAS-0015 reflects a broader shift in oncology toward precision medicine, where treatments are tailored to the genetic profile of a patient’s tumor. RAS mutations are present in approximately 30% of all human cancers, making them one of the most common drivers of tumor growth. A successful pan-RAS inhibitor could have far-reaching implications for patients with limited treatment options.

For patients with advanced pancreatic cancer, in particular, the need for effective therapies is urgent. Pancreatic cancer is often diagnosed at a late stage and has a five-year survival rate of just 12%. Current treatment options, including chemotherapy and targeted therapies, offer limited benefits, underscoring the importance of developing new approaches like ERAS-0015.

Similarly, non-small cell lung cancer remains a leading cause of cancer-related deaths worldwide. While immunotherapy and targeted therapies have improved outcomes for some patients, those with RAS mutations often have fewer effective treatment options. The high response rate observed in the ERAS-0015 trial suggests the drug could fill a critical gap in care for these patients.

What Comes Next

The next phase of clinical development will be crucial in determining whether ERAS-0015 can deliver on its early promise. Erasca is expected to present more detailed data at upcoming medical conferences and publish findings in peer-reviewed journals. Regulatory discussions with agencies such as the U.S. Food and Drug Administration (FDA) will also play a key role in shaping the drug’s path to market.

For now, the results offer a glimmer of hope for patients and families affected by some of the most challenging cancers. While the road to approval is long and uncertain, the early success of ERAS-0015 highlights the potential of innovative approaches to tackling historically difficult targets in oncology.

As the trial progresses, researchers and clinicians will be watching closely to see whether the drug’s benefits hold up in larger studies and whether it can ultimately change the standard of care for RAS-driven cancers.